222 related articles for article (PubMed ID: 33722977)
21. MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.
McAuley JR; Bailey KM; Ekambaram P; Klei LR; Kang H; Hu D; Freeman TJ; Concel VJ; Hubel NE; Lee JL; Klei HB; Cheng J; Sekar P; Bridwell RE; Covic L; Lucas PC; McAllister-Lucas LM
Oncogene; 2019 Dec; 38(49):7384-7398. PubMed ID: 31420608
[TBL] [Abstract][Full Text] [Related]
22. beta -Arrestins regulate protease-activated receptor-1 desensitization but not internalization or Down-regulation.
Paing MM; Stutts AB; Kohout TA; Lefkowitz RJ; Trejo J
J Biol Chem; 2002 Jan; 277(2):1292-300. PubMed ID: 11694535
[TBL] [Abstract][Full Text] [Related]
23. N-linked glycosylation of protease-activated receptor-1 at extracellular loop 2 regulates G-protein signaling bias.
Soto AG; Smith TH; Chen B; Bhattacharya S; Cordova IC; Kenakin T; Vaidehi N; Trejo J
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):E3600-8. PubMed ID: 26100877
[TBL] [Abstract][Full Text] [Related]
24. ARRDC3 suppresses breast cancer progression by negatively regulating integrin beta4.
Draheim KM; Chen HB; Tao Q; Moore N; Roche M; Lyle S
Oncogene; 2010 Sep; 29(36):5032-47. PubMed ID: 20603614
[TBL] [Abstract][Full Text] [Related]
25. Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT.
Zhu Y; Tao Z; Chen Y; Lin S; Zhu M; Ji W; Liu X; Li T; Hu X
Breast Cancer Res Treat; 2022 May; 193(1):65-81. PubMed ID: 35254603
[TBL] [Abstract][Full Text] [Related]
26. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
[TBL] [Abstract][Full Text] [Related]
27. Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion.
Booden MA; Eckert LB; Der CJ; Trejo J
Mol Cell Biol; 2004 Mar; 24(5):1990-9. PubMed ID: 14966279
[TBL] [Abstract][Full Text] [Related]
28. The Role of Arrestin Domain-Containing 3 in Regulating Endocytic Recycling and Extracellular Vesicle Sorting of Integrin β4 in Breast Cancer.
Soung YH; Ford S; Yan C; Chung J
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30545011
[TBL] [Abstract][Full Text] [Related]
29. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice.
Versteeg HH; Schaffner F; Kerver M; Ellies LG; Andrade-Gordon P; Mueller BM; Ruf W
Cancer Res; 2008 Sep; 68(17):7219-27. PubMed ID: 18757438
[TBL] [Abstract][Full Text] [Related]
30. Regulation of protease-activated receptor 1 signaling by the adaptor protein complex 2 and R4 subfamily of regulator of G protein signaling proteins.
Chen B; Siderovski DP; Neubig RR; Lawson MA; Trejo J
J Biol Chem; 2014 Jan; 289(3):1580-91. PubMed ID: 24297163
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells.
Soung YH; Pruitt K; Chung J
Sci Rep; 2014 Jan; 4():3846. PubMed ID: 24457910
[TBL] [Abstract][Full Text] [Related]
32. Occupancy of human EPCR by protein C induces β-arrestin-2 biased PAR1 signaling by both APC and thrombin.
Roy RV; Ardeshirylajimi A; Dinarvand P; Yang L; Rezaie AR
Blood; 2016 Oct; 128(14):1884-1893. PubMed ID: 27561318
[TBL] [Abstract][Full Text] [Related]
33. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
[TBL] [Abstract][Full Text] [Related]
34. Insights into β2-adrenergic receptor binding from structures of the N-terminal lobe of ARRDC3.
Qi S; O'Hayre M; Gutkind JS; Hurley JH
Protein Sci; 2014 Dec; 23(12):1708-16. PubMed ID: 25220262
[TBL] [Abstract][Full Text] [Related]
35. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.
Nouri K; Azad T; Lightbody E; Khanal P; Nicol CJ; Yang X
FASEB J; 2019 Nov; 33(11):12487-12499. PubMed ID: 31431076
[TBL] [Abstract][Full Text] [Related]
36. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer.
Bendinelli P; Maroni P; Matteucci E; Luzzati A; Perrucchini G; Desiderio MA
Eur J Cancer; 2013 Jul; 49(11):2608-18. PubMed ID: 23566416
[TBL] [Abstract][Full Text] [Related]
38. TAZ enhances mammary cell proliferation in 3D culture through transcriptional regulation of IRS1.
Janse van Rensburg HJ; Lai D; Azad T; Hao Y; Yang X
Cell Signal; 2018 Dec; 52():12-22. PubMed ID: 30138697
[TBL] [Abstract][Full Text] [Related]
39. Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro.
Chen B; Soto AG; Coronel LJ; Goss A; van Ryn J; Trejo J
Mol Pharmacol; 2015 Jul; 88(1):95-105. PubMed ID: 25934730
[TBL] [Abstract][Full Text] [Related]
40. Regulation of the thrombin/protease-activated receptor 1 axis by chemokine (C
Gao X; Cheng YH; Enten GA; DeSantis AJ; Gaponenko V; Majetschak M
J Biol Chem; 2020 Oct; 295(44):14893-14905. PubMed ID: 32839271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
